Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCND1 | P24385 | 18/20 | 0.56 |
| ▸ | CDK2 | P24941 | 17/20 | 0.56 |
| ▸ | CDK4 | P11802 | 12/20 | 0.56 |
| ▸ | CCND2 | P30279 | 9/20 | 0.56 |
| ▸ | CCND3 | P30281 | 9/20 | 0.56 |
| ▸ | CCNA2 | P20248 | 7/20 | 0.56 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.56 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.56 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.56 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.56 |
| ▸ | CCNA1 | P78396 | 6/20 | 0.53 |
| ▸ | CCNE1 | P24864 | 15/20 | 0.53 |
| ▸ | CDK6 | Q00534 | 9/20 | 0.53 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.53 |
| ▸ | CDK9 | P50750 | 3/20 | 0.53 |
| ▸ | CCNE2 | O96020 | 5/20 | 0.50 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.50 |
| ▸ | CDK1 | P06493 | 3/20 | 0.50 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.50 |
| ▸ | CCNB3 | Q8WWL7 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL574660 | 1.00 | CCND1 (0.56) | CCND1CDK2CDK4CCND2CCND3 | |
| SCHEMBL5263603 | 0.99 | CCND1 (0.57) | CCND1CDK2CDK4CCND2CCND3 | |
| SCHEMBL4828470 | 0.99 | CCND1 (0.57) | CCND1CDK2CDK4CCND2CCND3 | |
| SCHEMBL4828611 | 0.94 | CCND1 (0.49) | CCND1CDK2CDK4CCND2CCND3 | |
| SCHEMBL31637530 | 0.94 | CCND1 (0.49) | CCND1CDK2CDK4CCND2CCND3 | |
| SCHEMBL31153373 | 0.87 | CDK2 (0.58) | CCND1CDK2CDK4CCND2CCND3 | |
| SCHEMBL19857375 | 0.87 | CDK2 (0.58) | CCND1CDK2CDK4CCND2CCND3 | |
| SCHEMBL29507717 | 0.85 | CCND1 (0.42) | CCND1CDK2CDK4CCND2CCND3 | |
| SCHEMBL22860605 | 0.83 | CCND1 (0.40) | CCND1CDK2CDK4CCND2CCND3 | |
| SCHEMBL24669667 | 0.82 | CDK2 (0.53) | CCND1CDK2CDK4CCND2CCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4572755-A2 | CDK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| US-20250114461-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-04-10 | — | — | US | disclosed |
| CN-115702155-B | Novel pyrido [2,3-d ] pyrimidin-7 (8H) -one derivatives | 微境生物医药科技(上海)有限公司 | 2025-01-24 | — | — | CN | disclosed |
| US-20250018049-A1 | COMPOUNDS FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEOSOME PATHWAY | NIKANG THERAPEUTICS, INC. | 2025-01-16 | — | — | US | disclosed |
| CN-114394966-B | Pyridopyrimidinone CDK2/4/6 inhibitors | 辉瑞公司 | 2024-10-11 | — | — | CN | disclosed |
| WO-2024173646-A1 | CYCLIN-DEPENDENT KINASE DEGRADING COMPOUNDS | INNOVO THERAPEUTICS, INC. (US) | 2024-08-22 | — | — | WO | disclosed |
| CN-117715904-A | CDK2 degrading agents and uses thereof | 凯麦拉医疗公司 | 2024-03-15 | — | — | CN | disclosed |
| EP-4334307-A1 | CDK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| WO-2024039901-A2 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| CN-116390921-A | Heterocyclic compound with cyclin-dependent kinase inhibition activity, preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2023-07-04 | — | — | CN | disclosed |
| CN-115702155-A | Novel pyrido [2,3-d ] pyrimidin-7 (8H) -one derivatives | 微境生物医药科技(上海)有限公司 | 2023-02-14 | — | — | CN | disclosed |
| WO-2022236058-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250114461-A1 | CDK2 DEGRADERS AND USES THEREOF | CDK2, CDK20, CDK1 | CCND1 49/4885CDK2 1/4885CDK4 4/4885 |
| US-20250018049-A1 | COMPOUNDS FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEOSOME PATHWAY | CDK2, SKP2, CDK5 | CCND1 125/4885CDK2 1/4885CDK4 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.